Table 3.
Change in secondary outcomes from initial screening visit/baseline visit to the 24-week follow-up visit.a
| Estimated change | 95% CI | Pr(>|t|) | |
|---|---|---|---|
| Pre-bronchodilation FEV1(L) | 2.17% | [−0.23, 4.53] | 0.08 |
| Post-bronchodilation FEV1(L) | 3.5% | [−1.55, 8.51] | 0.17 |
| Pre-bronchodilation FVC (L) | 1.0% | [−1.65, 3.56] | 0.47 |
| Post-bronchodilation FVC (L) | 1.7% | [−0.97, 4.44] | 0.21 |
| Dartmouth COOP charts score | −1.97 | [−3.71, −0.23] | 0.03 |
| LCQ score | 1.11 | [0.08, 2.14] | 0.03 |
| SNOT-20 score | 1.34 | [−4.17, 6.86] | 0.64 |
| Serum 25(OH)D (nmol/L) | 134 | [114.40, 153.93] | 0.00 |
| Serum cathelicidin (ng/ml) | 126 | [72.46, 179.07] | 0.00 |
| Lund–Kennedy endoscopy score | −1.27 | [−1.54, −0.99] | 0.00 |
| Sputum 25(OH)D (nmol/L) | 2.66 | [−8.78, 14.1] | 0.63 |
| Sputum cathelicidin (ng/ml) | 526.62 | [−527.42, 1580.67] | 0.31 |
| Serum CRP (mg/L) | 2.0 | [−0.90, 4.85] | 0.17 |
| Serum ESR (mm/h) | 1.56 | [−1.05, 4.16] | 0.22 |
| Neutrophil count (109/L) | −0.05 | [−0.53, 0.42] | 0.81 |
FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; 25(OH)D: 25-hydroxyvitamin D; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; LCQ: Leicester Cough Questionnaire; SNOT-20: 20-Item Sino-Nasal Outcome Test; CI: confidence interval.
aThe LCQ, Dartmouth COOP charts and chronic rhinosinusitis symptoms score (SNOT-20) were administered at treatment initiation. FEV1 and FVC, which were performed at the initial screening and at treatment initiation, were averaged. The p values are for the change between the screening visit/treatment initiation and after 24 weeks of treatment.